Hologic Inc. (NASDAQ:HOLX) Receives $42.60 Consensus PT from Analysts
Shares of Hologic Inc. (NASDAQ:HOLX) have earned an average recommendation of “Buy” from the nineteen brokerages that are presently covering the firm. Six research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $42.60.
Several equities analysts recently commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Thursday, July 28th. Leerink Swann reaffirmed an “outperform” rating and set a $46.00 price target on shares of Hologic in a research report on Monday, October 3rd. Zacks Investment Research lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Evercore ISI raised shares of Hologic from a “hold” rating to a “buy” rating and upped their price target for the stock from $38.00 to $42.00 in a research report on Thursday, July 28th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $42.00 price target on shares of Hologic in a research report on Sunday, July 31st.
In other Hologic news, Director Nancy Leaming sold 6,221 shares of the stock in a transaction on Monday, July 11th. The shares were sold at an average price of $36.04, for a total transaction of $224,204.84. Following the transaction, the director now directly owns 55,053 shares in the company, valued at approximately $1,984,110.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.84% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Mizuho Asset Management Co. Ltd. increased its position in Hologic by 89.9% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,313 shares of the company’s stock worth $115,000 after buying an additional 1,568 shares during the period. J.Safra Asset Management Corp bought a new position in Hologic during the second quarter worth approximately $115,000. Invictus RG increased its position in Hologic by 577.0% in the second quarter. Invictus RG now owns 3,791 shares of the company’s stock worth $131,000 after buying an additional 3,231 shares during the period. Thompson Siegel & Walmsley LLC increased its position in Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares during the period. Finally, Synovus Financial Corp increased its position in Hologic by 35.6% in the second quarter. Synovus Financial Corp now owns 4,950 shares of the company’s stock worth $171,000 after buying an additional 1,300 shares during the period. Hedge funds and other institutional investors own 94.51% of the company’s stock.
Shares of Hologic (NASDAQ:HOLX) opened at 39.74 on Wednesday. The firm has a market capitalization of $11.02 billion, a price-to-earnings ratio of 43.81 and a beta of 1.00. The stock has a 50 day moving average of $38.44 and a 200-day moving average of $36.22. Hologic has a one year low of $31.84 and a one year high of $41.66.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The firm earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. During the same quarter in the prior year, the business posted $0.43 earnings per share. Hologic’s revenue for the quarter was up 3.4% compared to the same quarter last year. On average, equities analysts anticipate that Hologic will post $1.94 earnings per share for the current fiscal year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.